MAP2K7 and melanoma: Maio et al. [61] improved efficacy with intermittent MEK inhibition when combined with anti-PD-1 immunotherapy (pembrolizumab) in patients with advanced or metastatic BRAF-mutated solid tumors (36% colorectal cancer and 10% melanoma).